INFU · Infusystem Holdings, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $143.44M | $134.86M | $125.78M | $109.91M | $102.38M | $97.39M |
| Cost of Revenue | $63.14M | $64.46M | $62.68M | $47.34M | $42.19M | $38.63M |
| Gross Profit | $80.30M | $70.40M | $63.11M | $62.57M | $60.20M | $58.76M |
| R&D | - | - | - | - | - | - |
| SG&A | $56.97M | $51.21M | $45.38M | $46.08M | $42.26M | $35.20M |
| Total Operating Expenses | $68.38M | $63.51M | $59.02M | $60.92M | $57.38M | $49.93M |
| D&A | $13.29M | $12.50M | $12.51M | $13.36M | $14.63M | $14.03M |
| Operating Income | $11.92M | $6.89M | $4.09M | $1.65M | $2.82M | $8.83M |
| Interest Expense | $1.30M | $1.78M | $2.17M | $1.40M | $1.38M | $1.25M |
| Income Tax | $4.00M | $2.71M | $979.0K | $112.0K | ($163.0K) | ($9.79M) |
| Net Income | $6.63M | $2.35M | $872.0K | $18.0K | $1.42M | $17.33M |
| EPS - Basic | $0.32 | $0.11 | $0.04 | $0.00 | $0.07 | $0.86 |
| EPS - Diluted | $0.31 | $0.11 | $0.04 | $0.00 | $0.06 | $0.80 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.19M | $527.0K | $231.0K | $165.0K | $186.0K | $9.65M |
| Accounts Receivable | $22.90M | $21.16M | $19.83M | $16.87M | $15.40M | $14.72M |
| Inventory | $5.39M | $6.53M | $6.40M | $4.82M | $3.94M | $3.00M |
| Accounts Payable | $10.82M | $9.85M | $8.01M | $8.34M | $7.86M | $6.78M |
| Current Assets | $36.34M | $32.16M | $30.62M | $24.78M | $22.07M | $29.77M |
| Total Assets | $100.56M | $103.61M | $102.92M | $99.39M | $97.59M | $96.99M |
| Current Liabilities | $20.18M | $17.66M | $15.71M | $14.47M | $12.90M | $23.00M |
| Long-term Debt | $19.63M | $23.86M | $29.10M | $33.16M | $32.75M | $29.38M |
| Total Liabilities | $43.23M | $46.09M | $50.61M | $51.38M | $49.31M | $56.24M |
| Stockholders' Equity | $57.33M | $57.53M | $52.30M | $48.00M | $48.27M | $40.75M |
| Retained Earnings | ($60.70M) | ($57.46M) | ($58.63M) | ($59.34M) | ($53.90M) | ($44.03M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $24.41M | $20.46M | $11.22M | $17.52M | $18.32M | $20.28M |
| Investing Cash Flow | ($6.79M) | ($13.24M) | ($6.73M) | ($11.48M) | ($21.32M) | ($12.16M) |
| Financing Cash Flow | ($14.96M) | ($6.92M) | ($4.42M) | ($6.06M) | ($6.46M) | ($1.12M) |
| CapEx | $560.0K | $1.09M | $1.02M | $982.0K | $980.0K | $1.09M |
| Free Cash Flow | $23.85M | $19.37M | $10.20M | $16.54M | $17.34M | $19.19M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 56.0% | 52.2% | 50.2% | 56.9% | 58.8% | 60.3% |
| Operating margin | 8.3% | 5.1% | 3.2% | 1.5% | 2.8% | 9.1% |
| EBITDA margin | 17.6% | 14.4% | 13.2% | 13.7% | 17.0% | 23.5% |
| Net margin | 4.6% | 1.7% | 0.7% | 0.0% | 1.4% | 17.8% |
| Free cash flow margin | 16.6% | 14.4% | 8.1% | 15.0% | 16.9% | 19.7% |
| FCF / Net income | 3.60 | 8.26 | 11.70 | 918.61 | 12.21 | 1.11 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 39.7% | 38.0% | 36.1% | 41.9% | 41.3% | 36.1% |
| Effective tax rate | 37.6% | 53.6% | 52.9% | 86.2% | -13.0% | -129.8% |
| Return on assets | 6.6% | 2.3% | 0.8% | 0.0% | 1.5% | 17.9% |
| Return on equity | 11.6% | 4.1% | 1.7% | 0.0% | 2.9% | 42.5% |
| Return on invested capital | 9.7% | 4.2% | 2.5% | 1.0% | 3.5% | 12.6% |
| Liquidity | ||||||
| Current ratio | 1.80 | 1.82 | 1.95 | 1.71 | 1.71 | 1.29 |
| Quick ratio | 1.53 | 1.45 | 1.54 | 1.38 | 1.41 | 1.16 |
| Cash ratio | 0.16 | 0.03 | 0.01 | 0.01 | 0.01 | 0.42 |
| Leverage | ||||||
| Debt / Equity | 0.34 | 0.41 | 0.56 | 0.69 | 0.68 | 0.72 |
| Debt / Assets | 0.20 | 0.23 | 0.28 | 0.33 | 0.34 | 0.30 |
| Debt / EBITDA | 0.78 | 1.23 | 1.75 | 2.21 | 1.88 | 1.29 |
| Interest coverage | 9.2x | 3.9x | 1.9x | 1.2x | 2.0x | 7.0x |
| Equity multiplier | 1.75 | 1.80 | 1.97 | 2.07 | 2.02 | 2.38 |
| Liabilities / Assets | 0.43 | 0.44 | 0.49 | 0.52 | 0.51 | 0.58 |
| Efficiency | ||||||
| Asset turnover | 1.43 | 1.30 | 1.22 | 1.11 | 1.05 | 1.00 |
| Inventory turnover | 11.71 | 9.87 | 9.79 | 9.82 | 10.71 | 12.87 |
| Days sales outstanding | 58d | 57d | 58d | 56d | 55d | 55d |
| Days inventory outstanding | 31d | 37d | 37d | 37d | 34d | 28d |
| Days payable outstanding | 63d | 56d | 47d | 64d | 68d | 64d |
| Cash conversion cycle | 27d | 38d | 48d | 29d | 21d | 19d |
| Valuation | ||||||
| P / E | 28.9x | 76.8x | 263.5x | - | 283.8x | 23.5x |
| P / B | 3.3x | 3.2x | 4.4x | 3.9x | 7.8x | 10.0x |
| P / S | 1.3x | 1.4x | 1.8x | 1.7x | 3.7x | 4.2x |
| EV / EBITDA | 8.2x | 10.7x | 15.5x | 14.7x | 23.4x | 18.7x |
| Growth | ||||||
| Revenue growth (YoY) | 6.4% | 7.2% | 14.4% | 7.4% | 5.1% | 20.1% |
| Revenue CAGR (3y) | 9.3% | 9.6% | 8.9% | 10.7% | 12.9% | 11.1% |
| Revenue CAGR (5y) | 8.1% | 10.7% | 12.1% | 9.1% | 7.7% | 6.2% |
| Gross profit growth (YoY) | 14.1% | 11.6% | 0.9% | 3.9% | 2.4% | 25.3% |
| Operating income growth (YoY) | 73.0% | 68.6% | 147.2% | -41.3% | -68.1% | 150.4% |
| Net income growth (YoY) | 182.6% | 168.9% | 4744.4% | -98.7% | -91.8% | 1173.5% |
| EPS growth (YoY) | 181.8% | 175.0% | - | - | -92.5% | - |
| EPS CAGR (3y) | - | 22.4% | -63.2% | - | - | - |
| EPS CAGR (5y) | -17.3% | - | - | - | - | 38.0% |
| FCF growth (YoY) | 23.1% | 89.9% | -38.3% | -4.6% | -9.6% | 75.2% |
| FCF CAGR (5y) | 4.4% | 12.1% | -1.7% | 16.2% | 17.5% | 23.3% |
| Book value growth (YoY) | -0.4% | 10.0% | 9.0% | -0.6% | 18.5% | 82.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$263.71M totalPatient Services And Device Solutions$113.08M · 42.9%
Patient Services$86.53M · 32.8%
Device Solutions$64.10M · 24.3%
Product / service
$39.92M totalThird Party Payer Rentals$17.75M · 44.5%
Service$11.83M · 29.6%
Direct Payer Rentals$7.75M · 19.4%
Product$2.59M · 6.5%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.95
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
8/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing InfuSystem Holdings against the 5 most active filers in the same SIC group.